Rescape is a company pioneering the use of Virtual Reality (VR) in healthcare and frontline services. Its DR.VR platform, launched in 2019, helped reduce pain and anxiety amongst patients in hospitals and care homes. The company delivers VR content to patients through the Samsung Gear VR headset, a hard-plastic headset, that can be wiped down and disinfected along with VR sanitary eye masks that reduce chances of infection and irritation to patients. Through the company's technology, patients can experience ocean life, amusements parks and relax in some of the most beautiful settings in the world, all from the safety of the healthcare institution. The AR/VR in Healthcare Market is predicted to reach USD 30-40 billion by 2026, and Rescape aims to be a disruptor in this segment. The company will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£488,450
Strong and lightweight wheelchairs made using carbon fibre that attract attention to the person and not the disability. Carbon Black has developed elegant and beautiful wheelchairs, which compete with premium manual wheelchairs at similar prices. Further investment will help Carbon Black access key markets and establish a distribution service.
days to go:
Expired
investment:
£358,580
Coras is a new technology ticketing platform connecting the world's tickets to people who wish to buy them for any event or activity. The portal has connected multiple ticketing systems into a single system opening up this market to new players for the first time. Coras's marketplace suppliers include West End Theatre tickets, Premier League football and tourist attractions. On the distribution side, it has partnered with Europe's largest airline, Ryanair, Frontier Airlines in the US and Tix.co in Australia. It has also signed other distribution partners in Europe & Asia which it'll announce soon. Ticketing is a $150 billion industry and Coras wants to be a strong contender in this segment. The company will use 85% of investment in software development and build the best product possible that can scale with its distribution and supplier partners.
days to go:
Expired
investment:
£625,760
BioScore is a London-based health technology platform that enables you to easily visualize, track, and understand your fitness and health test results. It is currently designed as a software service for health and fitness professionals, gyms, personal trainers, sports coaches, sports clubs, schools, other allied health consultants and their clients. Leveraging on the trend of health optimization, BioScore aims to provide meaningful infographics and explanations, linked test histories, and personalised advice and action plans from fitness or health experts to their respective end-users, resulting in more effective diagnosis of ailments. The company will utilise the investment to develop an athlete management platform with an inspiring infographic, reporting and sell licences to access the platform's suite of online tools.
days to go:
Expired
investment:
£57,580
VPS work with vehicle manufacturers to provide labour such as fitting air conditioning, leather seats, etc. to their cars as they arrive at port from overseas. VPS's main focus is the manufacturing of Number Plates within the Approved British Standard and selling these directly to the car manufacturers.
days to go:
Expired
investment:
£851,620
EnXray are developing Low Energy X-ray (LEXR) technologies to sterilise equipment in commercial or research settings where low volume/high value therapeutic products, such as cancer vaccines and stem cell implants are being developed. Their aim is to reduce the need for third party providers and have the sterilisation process done on-site and on-demand with simple and safe equipment to reduce cost and save time for medical research organisations.
days to go:
Expired
investment:
£376,230
By combining fitness with fashion, art and design, BLOK has become a major competitor of boutique class-based gyms within London. BLOK has appeared on Britain's Next Top Model, as well as working with global stars including Anthony Joshua and Jordan Dunn.
days to go:
Expired
investment:
£891,790
TC BioPharm is an immunotherapy company. It has used its patented technology to harness the power of a particular part of the immune system, Gamma Delta T-cells (GDT), to negate cancer cells in the human body. TC BioPharm has treated terminally ill patients with acute myeloid leukaemia in approved clinical trials garnering positive responses from multiple patients. The company has received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to run a COVID-19 clinical trial to address the global pandemic. TC BioPharm aims to use its current technology to provide a frozen product that can be manufactured cost-effectively and distributed globally. The company has already raised over £7 million in the last 15 months. It will use the investment to take its clinical trials forward in COVID-19 and cancer.
days to go:
Expired
investment:
£1,753,067
Gravitricity is an energy technology company. The company uses winches to raise a heavyweight to the top of a vertical shaft to store electricity in the form of potential energy when there is excess energy on the grid. It then lowers it when required with the winch motors running as generators to transfer energy back to users on the grid. Gravitricity argues that the system can be charged and discharged multiple times a day for over 25 years. The company has built a 250kW concept demo in Edinburgh. It aims to become a contender in the energy storage market that is set to be worth $620 billion by 2040. The company has received interest from operating mines, grid companies, EV charging stations and solar developers for its technology. It is also investigating project sites in UK, Europe, the USA and South Africa. It will use the investment to complete the concept and detailed design for its prototype, develop its commercial projects portfolio, and protect its Intellectual Property (IP).
days to go:
Expired
investment:
£2,124,008
Greenwall Environmental Group is a company engaged in making devices that can minimise non-biodegradable waste. It argues that asbestos remains the largest occupational killer in the UK today. Its product, Asbestosprobe, aims to change this situation. The company asserts that Asbestoprobe is arguably the world's first handheld analyser specifically designed to detect asbestos in real-time. It argues that current methods of detecting and recording the presence of asbestos are costly, invasive and slow. Asbestoprobe uses a point-and-click approach utilising NIR Spectroscopy and Artificial Intelligence (AI) to analyse the presence of asbestos in two minutes via the Asbestoprobe App. Greenwall plans to provide an annual software licensing model which grows through recurring revenue year on year. It endeavours to be a segment leader in the projected $1 billion global asbestos management market. The company will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£253,017
